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1. Introduction 
Gene therapy can be defined as the process by which a normal functional copy of a gene is 
transferred into the appropriate cells of an individual with the intent to correct a disease 
caused by a defect within the individual’s own copy of the gene in question [1-3]. Gene 
therapy is still considered by many to be a relatively new therapeutic modality, having only 
developed over the last two decades. As such, it is still under intense experimental 
investigation to prove its therapeutic potential and safety before it can enter the clinic as a 
first line of treatment.  Gene therapy promises to offer a precise means of permanently 
curing essentially any of the over 4000 currently known so-called monogenic diseases, 
which are caused by an error in only a single gene.  These include, but are certainly not 
limited to, the hemophilias, lysosomal storage diseases like Gaucher’s and Hurler’s, 
hemoglobin disorders such as the thalassemias and sickle cell disease, diseases of immune 
function such as deficiencies in the shared ┛c receptor subunit or adenosine deaminase 
(ADA) deficiency,  and cystic fibrosis. It is also anticipated that gene therapy will one day 
enable the treatment of a host of inherited or acquired disorders such as cancer, AIDS, and 
many others for which there is currently no cure [4-9].     
2. Hemophilia a as an ideal target disease for correction with gene therapy 
Among the monogenic disorders, the hemophilias, and hemophilia A in particular, 
represent ideal diseases to attempt to treat with gene therapy [10-13] because lifelong 
improvement or permanent cure is theoretically possible after only a single treatment.  This 
is in contrast to current protein replacement-based therapies which, for hemophilia A, 
consist of frequent intravenous infusions of short-lived FVIII protein concentrates 
throughout the lifetime of the patient, without ever curing the underlying disease.  The 
severity of hemophilia A is traditionally based on plasma levels of FVIII, with persons 
exhibiting less than 1% normal factor (<0.01 IU/mL) being considered to have severe 
hemophilia, persons with 1-5% normal factor moderately severe, and persons with 5%-40% 
of the normal FVIII levels mild [14-16].  Thus, even with the low levels of transduction that 
are routinely obtained with the current viral-based gene delivery systems, a marked clinical 
improvement would be anticipated in patients with hemophilia A, since even low levels of 
FVIII would likely convert most patients with severe hemophilia to either a moderate or 
mild phenotype, greatly improving their quality of life.  Conversely, even supraphysiologic 
levels of FVIII as high as 150% of normal are predicted to be well tolerated, making the 
therapeutic window extremely wide [16].  In the past three decades, the remarkable 
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progress in the understanding of the molecular basis of the disease, the identification and 
characterization of FVIII gene, structure, and biology has furthered the interest and 
feasibility of treating hemophilia A with gene therapy. 
Based on the promise of lifelong cure following a single treatment and the encouraging 
preclinical results in murine and canine models, several clinical gene therapy trials in both 
hemophilia A and B have been undertaken.  In each case, the treatment was well tolerated 
with the vectors and doses used.  Despite the encouraging preliminary data from these 
studies [10, 13, 15-23], however, the plasma levels of FVIII achieved thus far have been 
insufficient to free the patients from the need of exogenous factor.  In addition, expression of 
the FVIII transgene was often transient, and none of the trials exhibited a clear relationship 
between vector dose and resultant FVIII levels.  Another major hurdle that has plagued the 
successful phenotypic correction of the hemophilias by factor replacement therapy is 
inhibitory antibody formation, which occurs in nearly 30% of patients with severe 
hemophilia A.  The formation of these inhibitors greatly reduces the efficacy of subsequent 
FVIII infusions, and can ultimately lead to treatment failure, placing the patient at risk of 
life-threatening hemorrhage.  Disappointingly, inhibitor formation has also observed when 
gene therapy has been used in an attempt to treat the hemophilias, since, as discussed in 
more detail below, the patient’s immune system still “sees” the vector-encoded FVIII or FIX 
as foreign. 
These clinical trials also raised the troubling possibility of inadvertent germline alteration 
when semen samples were found to be transiently positive for vector DNA [24, 25].  This is 
in contrast to prior studies conducted in experimental animals [26, 27], reinforcing the 
importance of the choice of animal model system employed when conducting pre-clinical 
studies, if one wishes to extrapolate results obtained in their model to what would likely 
happen in the clinic.  The occurrence of insertional mutagenesis-mediated leukemogenesis 
in children who received murine retroviral vector-transduced hematopoietic cells as 
treatment for X-SCID [28-30] further supports the need to perform detailed analyses in a 
clinically predictive animal model prior to moving into human patients, since an adverse 
event of this nature was never observed in the decades of animal gene therapy experiments 
that led up to these clinical trials.  
3. Animal models for testing gene therapy for hemophilia A 
A number of animal models have been developed to evaluate new methods of not only 
treatment of coagulation disorders, but also the prevention and treatment of inhibitor 
formation.  Dog models of hemophilia with congenital deficiency [31, 32] and mouse models 
obtained by gene targeting and knockout technology [33] are available to study FVIII 
function and gene therapy approaches for treating hemophilia A. Therapeutic benefit has 
been obtained in numerous studies using a variety of vector systems in the murine model 
[34-39], but phenotypic correction of hemophilia A in the dog has been much more difficult 
to achieve [40, 41], similar to findings in human patients, underscoring the value of large 
animal preclinical models for accurately predicting outcome in human patients.  Transient 
hemophilic rabbit models induced by infusion of plasma containing inhibitors have been 
used to evaluate the effect of different bypass products to factor VIII [42], but this model, 
while valuable for inhibitor studies, does not accurately recapitulate the human disease, 
precluding its use for gene therapy studies.  
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3.1 Sheep as a preclinical model of hemophilia A 
The ideal way to test gene therapy-based approaches to hemophilia A and evaluate long-
term expression of clinically applicable FVIII-encoding gene therapy vectors would be to 
use an animal model that both closely resembles the disease process of HA and closely 
parallels normal human physiology.  To this end, between 1979 and 1982, a number of male 
offspring of a single white alpine ewe at the Swiss Federal Institute of Technology all died 
several hours post-partum due to severe bleeding from the umbilical cord [43-45]. 
Daughters and granddaughters of this ewe also gave birth to lambs exhibiting the same 
pathology. Investigation of the affected animals showed extensive subcutaneous and 
intramuscular hematomas. Spontaneous hemarthroses were also frequent, leading to 
reduced locomotion and symptoms of pain in standing up, restricting nursing activity. 
Stronger injuries resulted in heavy bleeding and intensive pain. Laboratory tests showed 
increased PTT and FVIII levels (as assessed by aPTT) decreased to about 1% of that of the 
control animals. Replacement therapy with human FVIII (hFVIII) concentrate or fresh sheep 
plasma resulted in remission of disease and rapid clinical improvement. 
Unfortunately, due to the expense and effort of maintaining these sheep, the Swiss 
investigators allowed the line to die out, saving only 6 straws of semen prior to allowing this 
valuable resource to pass into extinction.  We recently used a variety of reproductive 
technologies to successfully re-establish this line of hemophilia A sheep and fully 
characterized both the clinical parameters and the precise molecular basis for their disease 
[46-51].  Importantly, chromogenic assays revealed undetectable FVIII activity in the 
circulation of these sheep, explaining their severe phenotype.  In addition, we identified a 
frame-shift-induced premature stop codon as the molecular cause of the disease, just as 
occurs in a percentage of human patients with hemophilia A, making this line of sheep 
unique among animal hemophilia A models, since hemophilia A mice were generated 
through targeted gene deletion and the hemophilia A dog colonies exhibit a gene inversion.  
In addition to the value of another large animal model of hemophilia A and the uniqueness 
of the mutation, sheep possess many characteristics that make them an ideal preclinical 
model for gene therapy, both postnatal and in utero.  Firstly, sheep are fairly close in size to 
humans, weighing roughly 8lbs at birth and 150-200lbs as adults, likely obviating the need 
for scale-up of vector dose to move from experiments in sheep to human trials.  In addition, 
the large size of the sheep, their long life span, and their relative ease of maintenance and 
breeding make it possible to conduct the long-term studies in large numbers of animals that 
are necessary to fully evaluate the efficacy and safety issues related to in utero gene therapy.  
Secondly, sheep share many important physiological and developmental characteristics 
with humans; for example, the pattern of fetal to adult hemoglobin switching, and the 
naturally occurring changes in the primary sites of hematopoiesis from yolk sac to fetal liver 
and finally to the bone marrow near the end of gestation.  It is thus not surprising that fetal 
sheep have been used extensively in the study of mammalian fetal physiology, and results 
obtained with this model have been directly applicable to the understanding of human fetal 
growth and development. Thirdly, sheep are outbred, and thus represent a wide spectrum 
of genetic determinants of the immune response, as do humans.  In addition, the 
development of the sheep immune system has been investigated in detail [52-58], making 
sheep well suited for studying the immunological aspects of gene therapy for HA.  As the 
immune response to both the vector and the vector–encoded FVIII are likely to play a key 
role in FVIII inhibitor formation (or lack thereof), this represents an advantage not found in 
most other models, with the possible exception of the dog.  For these reasons, we feel that 
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the sheep are a particularly relevant model in which to examine fetal gene therapy in 
general and, in particular, for hemophilia A. An additional unique advantage to using sheep 
to study hemophilia A treatment is that in sheep, like human, a large percentage of the vWF 
is found within platelets rather than free in plasma.  This is in contrast to dog (in which vWF 
circulates free in plasma [59, 60]), and may prove important given the vital role vWF plays 
in the stability/functionality of FVIII. 
4. Rationale for performing gene therapy in utero 
Importantly, many of the hurdles that have thus far prevented gene therapy from curing 
patients with hemophilia A, or many of the other diseases that have been investigated, 
could likely be circumvented by performing in utero gene therapy.  At the present time, 
many of the diseases considered as candidates for gene therapy can be diagnosed relatively 
early in gestation, making it feasible to begin devising methods for performing gene therapy 
in utero rather than waiting until after birth.  Methods for accessing both the sheep and the 
human fetus are well established and clinically viable.  Indeed, fetal transfusions and in 
utero stem cell-based therapies have now been performed clinically by numerous 
investigators for decades, using a variety of protocols, in efforts to treat patients with a 
number of different diseases [61, 62].  While the stem cell trials have thus far only proven 
clinically successful in patients with immunodeficiencies, they have also demonstrated that 
accessing the early gestational human fetus multiple times poses minimal risks with modern 
imaging and ultrasound-guided delivery procedures[63].  Furthermore, it is important to 
note that experience and knowledge gained from studies performed in the fetal sheep model 
were used to design and perform the first curative human in utero transplantation for X-
SCID [64], highlighting the value of the fetal sheep model for not only developing clinically 
viable methodology, but also for predicting clinical outcome.  Using these established 
clinically applicable methodologies to perform gene therapy early in gestation would correct 
the disease prior to parturition, allowing the birth of a normal healthy baby who, ideally, 
would require no further treatments. Additionally, following prenatal diagnosis of disease, 
parents currently have only two options; pregnancy termination or birth of an affected child.  
In utero gene therapy would provide a much needed third option [65].  Although in vitro 
embryo screening and selection is a possible solution, this option is not widely available due 
to both its high cost and the lack of the required technology in developing countries. In 
utero gene therapy, in contrast, does not require any sophisticated equipment that would 
not already be in place for prenatal diagnosis. Indeed, several recent studies have now 
conclusively demonstrated the marked cost-effectiveness of prenatal screening for the 
hemophilias, even within developing third world countries [66-68].   
Looking beyond the hemophilias, it is important to note that many of the diseases that could 
be treated with gene therapy exert a significant amount of irreversible damage to the patient 
prior to birth, during embryonic and fetal development.  For example, irreversible neuronal 
damage is associated with inherited metabolic diseases such as Gaucher’s, Lesch-Nyhan, 
and Tay Sachs.  In these patients, post-natal gene therapy, while potentially capable of 
correcting the metabolic disorder, would be of only limited therapeutic benefit, since it 
could not reverse the damage which the gene defect had exerted during development.  This 
is clearly in contrast to infants born with SCID or other genetic disorders, such as the 
hemophilias, who could theoretically be cured by postnatal gene therapy.  Nevertheless, 
even in patients with diseases that can be cured postnatally, psychological and financial 
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benefits exist to argue for performing correction in utero, since it would allow the birth of a 
healthy infant, who, ideally, would require no further treatments. 
5. The fetus as a gene therapy recipient 
In addition to the clinical and financial advantages of performing gene therapy prior to 
birth, numerous aspects of the fetus make it a more suitable gene therapy recipient than the 
adult.  For example, due to their ability to integrate into the genome of the host cell, ┛-
retroviruses and lentiviruses have received a great deal of attention as gene delivery vectors, 
since transduction of a long-lived cell could provide lifelong therapy following a single 
administration.  However, one of the main limiting factors to the successful application of 
these integrating vectors to in vivo gene therapy is the low level of initial transduction and 
the limited degree of expansion of transduced cells that occurs following gene therapy, since 
in the adult most cell populations in the body are relatively quiescent unless injury is used 
to induce cell cycling.  In the case of hemophilia A, the primary site of FVIII synthesis under 
normal physiologic conditions is the liver [69].  Yet, in a mature animal, it is estimated that 
only 1 in 10,000 to 1 in 20,000 hepatocytes are actively cycling at any given time [70], making 
it very difficult to obtain meaningful levels of gene transfer unless the gene delivery system 
mediates extremely high efficiency transduction of quiescent cells, or injury such as partial 
hepatectomy is employed to induce cell division to enhance transduction and/or drive 
expansion of the limited numbers of transduced cells. In the fetus, the cells in all of the 
organs are actively cycling to support the continuous expansion that occurs throughout 
gestation.  Thus, cells such as hepatocytes that are largely quiescent in the adult are far more 
mitotically active in the fetus. As such, these cells should be far more amenable to genetic 
correction with vectors requiring cell division.  Furthermore, the active cycling of the cells in 
all of the organs to support the continuous expansion that occurs throughout gestation 
offers the possibility of achieving expansion of the gene-corrected cells during the 
remainder of gestation, such that transduction of even small numbers of target cells should 
lead to significant levels of gene-correction by birth. 
6. Immunological advantages of in utero gene therapy 
It is important to note that many patients suffer from the genetic diseases being targeted 
with gene therapy because they have never produced a single specific protein.  As a result, 
their immune system has never “seen” this protein, and, following gene therapy, the cells of 
the immune system seek to eliminate any cells in the body that are expressing the very 
protein that could cure the patient of his/her disease.  The low levels of gene delivery to the 
desired target cells and the immune response combine to yield very low levels of expression 
of the therapeutic protein, and even the small amounts that are produced are often only 
produced for a short time.  In the case of hemophilia A, this cell-mediated immune response 
to the cells expressing the vector-encoded FVIII gene further complicates the already 
formidable challenge posed by the formation of inhibitory antibodies to the FVIII protein. 
Remaining cognizant of the immune-aspects of hemophilia treatment, it is important to note 
that, in addition to the ability to target cells which are largely refractory to transduction in 
the adult, unique immunologic advantages also exist for performing gene therapy in utero.  
There is a window of time in early immunologic development, before thymic processing of 
mature lymphocytes, during which the fetus is largely tolerant of foreign antigens. Exposure 
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to foreign antigens during this period often results in sustained tolerance, which can become 
permanent if the presence of the antigen is maintained [71].  When one considers that most 
individuals with a family history of hemophilia would likely go for early prenatal screening 
during pregnancy to ascertain whether the fetus was affected, it should be possible to 
perform in utero gene therapy relatively early in gestation.  Given these unique 
immunological advantages presented by the early fetus, one can envision that in utero gene 
therapy would be an ideal approach for treating hemophilia A, since lifelong tolerance 
could be induced to FVIII.  This would thus ensure that, even if in utero gene therapy was 
not curative, postnatal gene therapy or protein replacement could proceed safely without 
the risk of inhibitor formation.   
7. Experimental in utero gene therapy studies 
With the knowledge that performing gene therapy in utero would provide these advantages 
over existing post-natal approaches, we have spent the last decade and a half using the fetal 
sheep model to investigate whether it is possible to exploit the highly proliferative state and 
relative immuno-naïveté of the early gestational fetus to achieve significant levels of gene 
transfer by performing a single intraperitoneal injection of a ┛-retroviral vector [72-82].  This 
approach to in utero gene therapy is safe and technically simple, involving only a single 
injection into the peritoneum of the fetus, and the injection can easily be given under 
ultrasound guidance, greatly increasing the clinical applicability of the approach.  The 
straightforward nature of this approach enabled us to perform the gene transfer as early as 
54 days of gestation (term: 145 days), improving the chances of achieving clinical benefit in 
diseases with early onset, and potentially allowing induction of immune tolerance to the 
vector-encoded gene.   
8. Hematopoietic system 
We focused our initial efforts on assessing whether this approach resulted in transduction of 
primitive hematopoietic stem/progenitor cells (HSC), since transduced HSC should provide 
a lifelong supply of gene-modified hematopoietic progeny, enabling long-term correction 
following a single in utero treatment.  Based on the difficulty associated with transducing 
HSC in vitro without negatively affecting their in vivo engraftability/functionality [83], we 
reasoned that placing the vector directly in the fetus should conceivably expose all of the 
HSC present within the fetus to the vector while in their native microenvironment, 
potentially increasing the levels of gene transfer to the desired target cells.  Indeed, in our 
initial studies, we observed levels of 2-3% gene-marked hematopoietic cells in the 
circulation [81, 82].  Furthermore, we found that by varying the age of the recipient at the 
time of gene transfer, we could markedly enhance the levels of hematopoietic cell 
transduction [75, 84].. If gene transfer was performed at only 54-57 days of gestation, gene-
marking levels of 5-6% could be achieved in the peripheral blood, a level that could exert a 
beneficial effect in at least some genetic diseases.  Importantly, these gene-marked 
hematopoietic cells persisted in these sheep over the course of 5 years of study [81, 82], 
transgene-positive CD34+ cells could be detected in the bone marrow of these animals 
several years post in utero gene transfer [85], and bone marrow cells isolated from these in 
utero gene transfer recipients successfully engrafted the hematopoietic system of secondary 
fetal sheep recipients upon re-transplantation.  These three pieces of data provide 
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compelling evidence that this approach enabled us to successfully insert genes into the stem 
cells of the hematopoietic system, suggesting this method could provide lifelong genetic 
correction. 
9. Non-hematopoietic tissues 
While transduction of clinically significant levels of HSC within these sheep following a 
single injection of vector into the peritoneal cavity hinted at the therapeutic potential of this 
simple approach to in utero gene therapy, the retroviral vectors we employed in these 
studies did not possess any type of targeting moiety which would restrict transduction to 
cells of the hematopoietic system.  It was not surprising, therefore, when we examined other 
tissues of the recipients, to find that gene transfer was not limited to cells of the 
hematopoietic system, but had occurred in essentially all of the organs we examined, 
including numerous cell types within the liver, lung, and brain [79, 81, 82, 86].  
Concomitantly, in utero gene transfer studies performed by other investigators in sheep, 
rodent, and non-human primate models employing a variety of viral-based gene delivery 
vectors produced similar results [78-81, 87-105], raising the exciting possibility that in utero 
gene therapy could potentially be used to treat not only hematologic disorders, but also 
numerous genetic disorders that affect tissues other than the hematopoietic system.  For 
example, in the case of the hemophilias, this method could likely be used with success to 
delivering genes for the missing coagulation factors to the developing liver at levels that 
would covert patients with severe hemophilia to a moderate or even mild phenotype [79].  
Moreover, tissue-specific expression is not necessary for factor VIII (the factor deficient in 
hemophilia A) or factor IX (the factor deficient in hemophilia B).  Thus, the transfer of either 
of these genes into a wide range of tissues with ready access to the circulation, followed by 
long-term expression, would greatly enhance the therapeutic potential of this approach for 
treating/curing the hemophilias.   Interestingly, although the incidence of hemophilia A is 
7x’s that of hemophilia B, the only studies that have explored the possibility of performing 
in utero gene therapy for the treatment of the hemophilias have been aimed at correcting 
hemophilia B (factor IX deficiency), and all but one group’s studies [88, 99] have been 
performed in mice [87, 100, 101, 103-105], making it somewhat difficult to extrapolate the 
results to the human clinical setting. 
Despite offering many advantages in the treatment of diseases such as the hemophilias, the 
widespread presence of gene-modified cells throughout the body also underscored the need 
to carefully examine the safety of this approach to in utero gene therapy, since expression of 
the transferred genetic material in all tissues may not always be desirable, and, in some 
cases, could in fact be deleterious, if the transgene in question requires tissue-specific 
expression. Based on our observations in the hematopoietic system, we first examined 
whether the developmental stage of the recipient might impact upon which tissues were 
modified following in utero gene therapy.  Our initial results revealed that the liver, like the 
hematopoietic system, is more amenable to gene transfer at earlier stages of fetal 
development, leading us to believe that perhaps gene transfer was always most efficient if 
performed earlier in gestation.  However, when we examined the lungs of these same 
recipients, we discovered that this belief was unfounded.  In the lungs we observed exactly 
the opposite of what we had seen in the hematopoietic system and the liver, namely, that 
the levels of gene-marked cells were much higher if the transfer was performed later in 
gestation [79, 86]. These findings thus suggest that each tissue likely possesses its own 
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unique developmental stage during which gene transfer is optimal.  These findings also 
raised the intriguing possibility that it may be possible to choose, at least to some degree, 
which tissues will be modified following in utero gene transfer, by carefully selecting the 
age at which the transfer is performed. 
10. Induction of immune tolerance following in utero gene transfer 
As discussed previously, one of the major hurdles hindering treatment of the hemophilias 
by factor replacement therapy is the formation of inhibitory antibodies that can occur with 
repeated administration of these exogenous factors over time.  While analyzing the tissues 
from the sheep that received in utero gene transfer, we noted that the thymus frequently 
exhibited transgene-positivity by PCR [81, 82].  Given the pivotal role of the thymus during 
the development of the fetal immune system’s ability to distinguish self from non-self, we 
undertook studies to ascertain the immunologic significance of the presence of these 
transgene-positive cells within the thymus. In our first set of studies, [106] we demonstrated 
that in utero gene transfer successfully induced durable immune tolerance to the vector-
encoded ┚-galactosidase.  This tolerance induction appeared to involve both cellular and 
humoral mechanisms, since both antibody responses and cellular responses were blunted in 
these animals even several years after in utero gene transfer, providing strong evidence that 
IUGT induces immune tolerance to the protein product of the transgene.  We next 
conducted studies to begin elucidating the mechanisms responsible for this observed 
tolerance and to assess whether the recipient gestational age had an impact upon transgene 
immunity/tolerance induction [107]. Immunohistochemistry revealed that thymic tissue is 
in fact transduced in the majority of animals following IUGT regardless of the age at which 
in utero gene transfer is performed. Importantly, however, we only observed transduction 
of thymic epithelial cells that are crucial for presentation of self-antigen during T cell thymic 
selection if gene transfer was performed prior to 72 days of gestation [term: 145 days], while 
after that point in gestation, predominantly CD45+ thymocytes were transduced. These 
analyses also revealed that, if in utero gene transfer is performed early in gestation, 
epithelial-like cells comprising the Hassall’s corpuscles, as evidenced by their morphology, 
their CK-positivity, and their expression of thymic stromal lymphopoietin are also 
transduced. Flow cytometric analysis on the animals that received in utero gene transfer at 
varying gestational ages revealed that animals that received gene transfer early in gestation 
had significantly higher percentages of CD4+CD25+ Tregs within their periphery than did 
control animals or animals transduced later in gestation.  These studies thus demonstrate 
that performing in utero gene transfer early in gestation takes advantage of multiple 
tolerogenic avenues present in the fetus, since it results in the transduction of both thymic 
epithelial cells, which may promote induction of central immune tolerance, and cells of 
Hassall’s corpuscles, which can instruct dendritic cells to induce Tregs that can help 
maintain peripheral immune tolerance to the transgene products. These findings thus 
suggest that, even if not curative, in utero gene therapy would be ideal for a disease like 
hemophilia A, since lifelong tolerance could be induced to FVIII, thus overcoming the 
immune-related hurdles that currently hinder post-natal treatment of this disease.  As 
discussed previously, however, in utero gene therapy studies to date have focused on 
hemophilia B [87, 88, 99-101, 103-105], rather than hemophilia A, which is intriguing, given 
the 7-fold higher incidence of hemophilia A, and the fact that patients with hemophilia A 
are more than 10x’s as likely to develop inhibitory antibodies to the exogenous coagulation 
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factor than patients with hemophilia B [108, 109].  While the choice to focus on hemophilia B 
is likely due to difficulties encountered in initial attempts to express FVIII as a transgene in 
the context of viral vectors [110], it nevertheless makes it unclear whether the ability to 
induce immune tolerance to marker gene products and FIX in utero will ultimately translate 
into the ability to induce tolerance to FVIII, given FVIII’s apparent higher degree of 
immunogenicity.   
11. Potential risk to fetal germline 
While gene transfer to the vast majority of the fetal tissues would be desirable for correcting 
diseases, such as the hemophilias, that would benefit from widespread systemic release of a 
secreted transgene product, our analyses also revealed that the fetal reproductive tissues 
often contained the gene therapy vector sequences, raising the troubling possibility that the 
developing germline might have been modified as a result of in utero gene therapy.  Since 
prior studies had demonstrated that both the embryonic germline [111-114] and isolated 
primordial germ cells (PGC) [115] can readily be infected with murine retroviral vectors and 
pass the vector genetic material to subsequent generations in a Mendelian fashion as part of 
the permanent genome, we used three approaches to examine this important issue in detail: 
1) We performed immunohistochemical staining on tissue sections prepared from the in 
utero treated animals; 2) we performed genetic analysis on the sperm cells from the treated 
males; and 3) we performed breeding experiments in a limited number of animals [72, 80, 
91, 116, 117].  These studies indicated that although the fetal ovaries appeared to be largely 
unaffected by this approach to in utero gene transfer, numerous cells within the developing 
fetal testes were in fact modified including interstitial cells, Sertoli cells, and small numbers 
of both immature germ cells within the forming sex cords and the resultant sperm cells.  
Importantly, however, gene-modified germ cells were only observed in 2 of the 6 animals 
examined in our studies, and, in these two animals, the incidence of germ cell modification 
was roughly 1 in 6250, a frequency that is well below the theoretical level of spontaneous 
mutation within the human genome [118].  This low frequency of modification coupled with 
observations that genetic alterations to the germ cells may produce deleterious effects, 
placing them at a disadvantage during fertilization suggest that the likelihood that any 
genetic alterations present would be passed to subsequent offspring would be extremely 
unlikely.  In agreement with this supposition, we did not observe transfer of the vector 
sequences in any of the 10 offspring we studied, even when both the parents had received 
gene transfer in utero.  This is clearly an issue that will need to be addressed in greater 
detail, nevertheless, prior to moving in utero gene therapy into clinical trials. This need for 
further investigation is underscored by the fact that, in other studies employing lentiviral 
vectors in non-human primates, the authors observed modification of the female germline, 
but no effect upon the male germ cells [90].  Thus, the issue of germline safety will likely 
have to be investigated in more than one preclinical model, and the specific vector being 
considered for clinical use will have to be employed, in order to obtain an accurate 
assessment of the risk posed by the procedure.  
12. Conclusions 
In conclusion, our findings in the sheep model and those of other groups exploring fetal 
gene delivery in sheep, mouse, and non-human primate substantial evidence now exists that 
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in utero gene therapy possesses many advantages over postnatal gene therapy, both from a 
scientific standpoint and from a socioeconomic/psychological point of view, since it is one 
of the only therapies that could promise the birth of a normal healthy infant following 
prenatal diagnosis of disease.  Importantly, in our in utero studies, none of the sheep that 
received murine MoLV-based vector preparations exhibited any type of pathology upon 
examination, even at time points of greater than 5 years post-transduction.  Given the highly 
proliferative state of the fetus at the time of injection, the transduction of repopulating HSC, 
and the chance of insertional mutagenesis as a result of MoLV genomic integration, the lack 
of pathology within these animals is a finding of significance, and suggests that although 
not ideal, MoLV-based vectors may be relatively safe, at least in this context.  Equally 
importantly, the risk to the fetus appears to be minimal, at least when administering the 
vector via the peritoneal cavity.  Following in utero gene transfer, multiple tissues of the 
developing fetus were transduced and transgene expression persisted long-term (over 5 
years), suggesting that this approach may one day be a viable therapeutic option for 
diseases affecting any of the major organ systems.  Moreover, even if not curative, in utero 
gene therapy would be ideal for a disease like hemophilia A, since lifelong immunologic 
tolerance could be induced to FVIII, thus overcoming the immune-related hurdles that 
currently hinder post-natal treatment of this disease.  Despite its great potential, however, it 
is important to realize that in utero gene therapy is still in the experimental stages and many 
issues need to be clarified before it can become a clinically viable treatment option for 
hemophilia A or any of the host of other monogenic diseases.  Nevertheless, having recently 
re-established an extinct line of sheep with hemophilia A [43-45, 47-51] that accurately 
recapitulate the genetics and clinical symptoms of human patients with severe hemophilia 
A, we are now in an ideal position to apply our experience with in utero gene delivery and 
this clinically predictive large animal model to begin developing safe and effective 
approaches to treat hemophilia A with in utero gene therapy.   
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